Psychedelic Business Spotlight – March 18
This week in psychedelic business news: A psychedelics company folds; Ketamine Wellness Centers expand; Nova Mentis funds psilocybin studies.
Author: Greg Gilman
Mind Cure Health Halts All Psychedelic Business Activity
The company was pursuing several psychedelic business strategies, including synthesizing ibogaine for researchers.
Psychedelic Business Spotlight- March 11
This week in psychedelic business news: Small Pharma prepares big DMT studies; Health Canada approves a psilocybin PTSD study.
Psychedelic Business Spotlight – March 4
This week in psychedelic business news: Field Trip partners with Cerebral; Benzinga forms Psychedelic Advisory Council; Incannex pursues virtual reality psychedelic therapy.
The Biggest Reason People in Oregon Want to Use Psilocybin
Spoiler alert: It’s not because they’re depressed.
Psychedelic Business Spotlight – February 25
This week in psychedelic business news: Core One cheapens psilocybin production; Field Trip eyes Oregon; Small Pharma advances DMT.
LSD Microdosing Study Finds ‘No Residual Effects’ on Mood or Cognition
Another study concludes with results challenging the increasingly popular narrative that microdosing psychedelics improves mood and cognitive function.
4 Signs the Psychedelics Movement Is Unstoppable
With no strong resistance manifesting to oppose the psychedelic renaissance, it appears these drugs have re-emerged from underground for a permanent place in our culture.
Psychedelic Business Spotlight – February 18
This week in psychedelic business news: Nova Mentis makes progress on autism; atai donates to MAPS; Cathie Wood eyes more psychedelic stocks.
Judge Grants Hearing for Opposition to DEA Proposal to Criminalize 5 More Psychedelics
Biotech companies and researchers opposed to five more tryptamines becoming schedule 1 controlled substances will present their case this spring.
End of content
End of content